Op-eds: Canadian and American regulators, law enforcement and patient advocates oppose drug importation
Since 2000, every head of the United States Food and Drug Administration (FDA) and United States Department of Health and Human Services (HHS) has opposed drug importation because the benefits that might be gained are far outweighed by the many dangers. Law enforcement, patient advocates, pharmacy groups, and regulators agree.
Investor’s Business Daily published this editorial by D. Wayne Taylor, Executive Director of the Cameron Institute, a not-for-profit, public policy think tank specializing in the independent study of health, social and economic issues both in Canada and around the world.
On June 23, 2017, MorningConsult published this editorial by Garfield Clunie and Richard Williams. Clunie is the chairman of the board of the National Medical Association, a 501 (c) (3) nonprofit that represents African American physicians and their patients. Williams is the organization’s president.
Pharmacy boards, which ensure the safety of prescription medicines at the state level, have been sending letters to Congress to expressing significant safety concerns about legislation that would legalize drug importation.
The Salt Lake Tribune printed this editorial by Tom Ridge, the 43rd governor of Pennsylvania and first secretary of the U.S. Department of Homeland Security, on June 10, 2017. Ridge is currently a senior advisor to Americans for Securing All Packages (ASAP).
Kevin St. James, Commissioner of Rockingham County in New Hampshire is very concerned that Congressional representatives will pass drug importation legislation without giving any thought to the explosive impact that opening our borders to drug shipments will have on America’s deadly opioid/fentanyl crisis.
The most recent editorial in Stat advocating black market drug importation under the guise of “ordering prescription drugs abroad” overlooks many safety dangers. The most important oversight is in the characterization of the cost of medications. Over 80% of all medications dispensed in the U.S. are dispensed as generic, and generics as a whole are…
This editorial was published by the Institute for Policy Innovation on June 5, 2017. Its author, Dr. Merrill Matthews, is a resident scholar with the Institute for Policy Innovation, a health policy expert and contributor at Forbes.com. He also serves on the Texas Advisory Committee of the U.S. Commission on Civil Rights.
On June 1, 2017, the American Pharmacists Association (APhA), which represents 64,000 pharmacy professionals, and the National Association of Chain Drug Stores (NACDS), which represents more than 100 national and regional pharmacy chains, sent a letter to President Donald Trump urging him not to support legislation that would allow broad personal and commercial importation of non-FDA approved prescription drugs.
This editorial by Scott Bertani was published in the Washington Herald on May 7, 2017. Mr. Bertani is the Director of Policy and Community Relations for Lifelong AIDS Alliance, a nonprofit health advocacy group based in Western Washington.
This editorial by Derek Arnson appeared in the Washington Examiner on May 8, 2017. Mr. Arnson is the former Chief of Police in Nogales, Arizona.